Bridge Biotherapeutics Conducts 'Company Presentation' at BIO USA

[Asia Economy Reporter Chunhee Lee] Bridge Biotherapeutics announced on the 26th that it will hold a company presentation at the '2022 BIO International Convention (BIO USA)' to be held in the United States next month.

BIO USA is the world's largest pharmaceutical and bio industry partnering event. It will be held for four days from the 13th to the 16th of next month (local time) in San Diego, California, USA. Especially this year, it is expected to attract significant attention from the industry as it will be held fully offline for the first time in over three years since 2019, with many global pharmaceutical and bio companies attending.

Bridge Biotherapeutics will conduct its first in-person company presentation at BIO USA this year. A 13-minute in-person company presentation is confirmed for 11:45 AM on the 16th at 'Company Presentation Theater 3'. Pavel Prinsev, Director of Business Development, will deliver the presentation covering the next-generation targeted therapy candidates 'BBT-176' and 'BBT-207', the oncology pipeline, and key development projects centered on 'BBT-401' and 'BBT-877', as well as major business strategies and future growth vision. Through this, the company plans to interact with global pharmaceutical and bio companies, share the latest development status of key projects, and actively seek various business development opportunities.

Jungkyu Lee, CEO of Bridge Biotherapeutics, stated, “We will use BIO USA as an opportunity to actively promote the achievements of our main research and development projects,” and added, “We plan to accelerate concrete discussions on global business development strategies and execution directions through numerous partnering meetings.”

This content was produced with the assistance of AI translation services.